Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Epicardial fat volume linked to coronary artery disease

28 Jun 2020

Epicardial fat volume (EFV) appears to coincide with greater coronary artery calcification (CAC) and obstructive coronary artery disease (CAD) in patients with symptoms of cardiovascular disease, a new study has found.

The study included 1,344 patients, of whom 63.1 percent (n=848) had no CAD, while 24.3 percent (n=326) had nonobstructive CAD. The remaining 170 (12.6 percent) had obstructive CAD. Mean CAC was 56.5 and was absent in 28.3 percent (n=380). The median EFV was 90.52 mL.

Median CAC was lower in those without CAD, as opposed to either group with CAD. In turn, patients with obstructive vs nonobstructive CAD showed higher median CAC values (15 vs 113.5 vs 427). Both pairwise comparisons were statistically significant (p<0.001 for both).

Similarly, median EFV was reduced in participants who had no CAD, as opposed to those with nonobstructive and obstructive CAD (87.21 vs 93.89 and 102.98 mL; p<0.001). The difference in EFV between the two CAD subgroups failed to reach significance.

However, full logistic regression models showed that EFV was inconsistently predictive of either nonobstructive (B, 1.002, 95 percent confidence interval [CI], 0.999–1.005; p=0.204) or obstructive (B, 1.002, 95 percent CI, 0.998–1.006; p=0.325) CAD.

CAC, on the other hand, reliably differentiated obstructive from nonobstructive CAD (B, 1.00, 95 percent CI, 0.999–1.000; p<0.001) and from no CAD (B, 1.000, 95 percent CI, 0.998–1.006; p<0.001). However, CAC had limited value in discriminating no CAD from nonobstructive CAD (B, 1.000, 95 percent CI, 1.000–1.000; p=0.869).

“CAC is a predictor of CAD presence and severity, while EFV did not predict the burden of CAD,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.